Investigational dual orexin receptor antagonist almorexant meets primary endpoint

In RESTORA 1, the use of almorexant was well-tolerated. However, in this study as well as in the ongoing non-pivotal program, certain safety observations were made that will require further evaluation and assessment in longer-term Phase III studies. The Phase III studies are currently in preparation - in both adults and elderly patients suffering from primary insomnia - and will evaluate long-term efficacy and safety.

Professor Jed Black, M.D. and VP Sleep Development at Actelion, commented: "In this two- week study, almorexant has demonstrated clinically meaningful effects on both sleep induction and sleep maintenance for patients suffering from primary insomnia. I am especially encouraged that these effects were maintained both throughout the night and throughout the 16-day treatment period."

Jean-Paul Clozel, M.D and Chief Executive Officer of Actelion, commented: "As a result of the use of an active reference arm of zolpidem 10mg in RESTORA 1, we have now obtained a first promising insight of the impact of our dual orexin receptor antagonist almorexant compared to the impact of a traditional GABA-agonist."

Jean-Paul Clozel concluded: "Additional studies are being planned to further establish the clinical profile of almorexant. We will explore aspects of sleep quality, absence of addiction and improved next-day performance. Chronic use studies in both adults and elderly will further evaluate the safety profile of this innovative agent."

--- END press release Investigational dual orexin receptor antagonist almorexant meets primary endpoint ---

  Actelion Pharmaceuticals Ltd (company entry)